Your browser doesn't support javascript.
loading
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.
Hamasaki, Toshimitsu; Asakura, Koko; Evans, Scott R; Sugimoto, Tomoyuki; Sozu, Takashi.
Afiliación
  • Hamasaki T; Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, Japan ; Department of Innovative Clinical Trials and Data Science, Osaka University Graduate School of Medicine, Japan.
  • Asakura K; Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, Japan ; Department of Innovative Clinical Trials and Data Science, Osaka University Graduate School of Medicine, Japan.
  • Evans SR; Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, USA.
  • Sugimoto T; Department of Mathematical Sciences, Hirosaki University Graduate School of Science and Technology, Japan.
  • Sozu T; Department of Biostatistics, Kyoto University School of Public Health, Japan.
Stat Biopharm Res ; 7(1): 36-54, 2015.
Article en En | MEDLINE | ID: mdl-25844122
ABSTRACT
We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, i.e., potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Stat Biopharm Res Año: 2015 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Stat Biopharm Res Año: 2015 Tipo del documento: Article País de afiliación: Japón